- Title
- Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy
- Creator
- Denham, James W.; Steigler, Allison
- Relation
- Seminars in Radiation Oncology Vol. 23, Issue 3, p. 206-214
- Publisher Link
- http://dx.doi.org/10.1016/j.semradonc.2013.01.008
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2013
- Description
- The optimal duration of hormonal therapy when combined with radiation for men with high-risk and locally advanced prostate cancer remains under active study. Based on the results of randomized controlled trials, durations of androgen suppression therapy of at least 6 months have been shown to prolong survival in men with Gleason score 7 prostate cancer, irrespective of clinical stage. For men with locally advanced prostate cancer and 2 high-risk factors (particularly Gleason 8-10 tumors with evidence of extracapsular extension or seminal vesicle invasion on digital rectal examination) or pelvic nodal involvement, longer durations of 28-36 months appear best, although shorter durations (eg, 18 months) remain under study. Trials are also ongoing to determine whether radiation dose escalation and/or nonhormonal agents, such as zoledronic acid and docetaxel, will reduce the need for supplementary androgen suppression therapy.
- Subject
- prostate cancer; radiotherapy; hormone therapy; zoledronic acid
- Identifier
- http://hdl.handle.net/1959.13/1067935
- Identifier
- uon:18511
- Identifier
- ISSN:1053-4296
- Language
- eng
- Reviewed
- Hits: 998
- Visitors: 999
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|